Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

NCT03137784 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: NVA237 (glycopyrronium bromide)
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals